PF 06273340

Pricing Availability   Qty
Cat.No. 6115 - PF 06273340 | C23H22ClN7O3 | CAS No. 1402438-74-7
Description: Potent and selective pan-Trk inhibitor; peripherally restricted
Chemical Name: N-[5-[[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]-3-pyridinyl]-5-chloro-2-pyridineacetamide
Purity: ≥98% (HPLC)
Reviews (1)
Literature (6)

Biological Activity for PF 06273340

PF 06273340 is a potent and selective pan-Trk inhibitor (IC50 values are 1, 2 and 6 nM for Trk C, B and A, respectively). Selective for Trk over a panel of ion channels, receptors and other enzymes. Peripherally restricted. Exhibits efficacy in a rodent model of inflammatory pain. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Compound Libraries for PF 06273340

PF 06273340 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for PF 06273340

M. Wt 479.93
Formula C23H22ClN7O3
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 1402438-74-7
PubChem ID 66571548
Smiles NC1=NC=C2C(N(C(C)(C)CO)C=C2C(C3=CN=CC(NC(CC4=CC=C(Cl)C=N4)=O)=C3)=O)=N1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for PF 06273340

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 47.99 100

Preparing Stock Solutions for PF 06273340

The following data is based on the product molecular weight 479.93. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.08 mL 10.42 mL 20.84 mL
5 mM 0.42 mL 2.08 mL 4.17 mL
10 mM 0.21 mL 1.04 mL 2.08 mL
50 mM 0.04 mL 0.21 mL 0.42 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for PF 06273340

References are publications that support the biological activity of the product.

Skerratt et al (2016) The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain. J.Med.Chem. 59 10084 PMID: 27766865

If you know of a relevant reference for PF 06273340, please let us know.

View Related Products by Product Action

View all Trk Receptor Inhibitors

Keywords: PF 06273340, PF 06273340 supplier, PF06273340, Trk, A, B, C, tropomyosin-related, kinase, receptors, neurotrophins, inhibitors, inhibits, peripherally, restricted, potent, selective, Receptors, 6115, Tocris Bioscience

Citations for PF 06273340

Citations are publications that use Tocris products.

Currently there are no citations for PF 06273340. Do you know of a great paper that uses PF 06273340 from Tocris? Please let us know.

Reviews for PF 06273340

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used PF 06273340?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Assessing the efficacy on cancer cells.
By Anonymous on 09/08/2017
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: cancer cell line

Measured cancer cell viability upon treatment with this drug at various concentrations including 5 and 10 uM. In addition, compared it to a specific siRNA.

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis

Kinases Product Listing

A collection of over 400 products for kinase research, the listing includes inhibitors of:

  • Receptor Tyrosine Kinases
  • Protein Kinases A, C, D and G
  • PI-3 Kinase, Akt and mTOR
  • MAPK Signaling
  • Receptor Serine/Threonine Kinases

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.


Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.